Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07326839 (Optimization of Blood Uric Acid Control in Obese Gout Patients by Orlistat-Mediated Metabolic Remodeling and Intensive Weight Management), which is not on this map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07326839 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation
Optimization of Blood Uric Acid Control in Obese Gout Patients by Orlistat-Mediated Metabolic Remodeling and Intensive Weight Management: A Randomized Controlled Trial
TypeinterventionalSponsorXueMei GuoRan2025 to 2027Enrolled120ConditionsGout, ObesityArmsOrlistat 120 mg, Allopurinol 100 up to 600mg/day, Febuxostat 40mg Tab
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Hyunsue DoDivision of Rheumatology, Department of Internal Medicine, Kangwon National University School of Medicine, 1 Kangwondaehak-gil, Chuncheon, 24341, South Korea.ORCID 0000-0002-9550-1048
Hyo Jin ChoiDivision of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea.ORCID 0000-0001-5192-6151
Byoongyong ChoiDivision of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Seoul Medical Center, Seoul, South Korea.ORCID 0000-0002-6118-155X
Chang-Nam SonDivision of Rheumatology, Department of Internal Medicine, Eulji University School of Medicine, Uijeongbu, South Korea.ORCID 0000-0002-1722-2190
Sang-Hyon KimDivision of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.ORCID 0000-0002-8030-7939
Se Rim ChoiDivision of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.ORCID 0000-0002-4625-8571
Ji Hyoun KimDivision of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, South Korea.ORCID 0000-0003-0765-347X
Min Jung KimDivision of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea.ORCID 0000-0002-2618-1415
Kichul ShinDivision of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea.ORCID 0000-0002-6749-7598
Hyun-Ok KimDivision of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea.ORCID 0000-0002-0904-1584
Ran SongDivision of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea.ORCID 0000-0003-0104-4091
Sung Won LeeDivision of Rheumatology, Department of Internal Medicine, Soon Chun Hyang University Hospital, Cheonan, South Korea.ORCID 0000-0002-1981-742X
Joong Kyong AhnDivision of Rheumatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.ORCID 0000-0003-3246-4435
Seung-Geun LeeDivision of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea.ORCID 0000-0002-5205-3978
Chang Hoon LeeDivision of Rheumatology, Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, South Korea.ORCID 0000-0002-7351-3806
Kyeong Min SonDivision of Rheumatology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Gyeonggi-do, South Korea.ORCID 0000-0002-7948-9624
Ki Won MoonDivision of Rheumatology, Department of Internal Medicine, Kangwon National University School of Medicine, 1 Kangwondaehak-gil, Chuncheon, 24341, South Korea. kiwonmoon@kangwon.ac.kr.ORCID 0000-0002-4182-8328
Funding
NIEHS NIH HHS 27307C0010
6 · The paper itself
Abstract
Achieving target serum uric acid (SUA) levels is important in gout management. Guidelines recommend lowering SUA levels to < 6 mg/dL; however, many patients fail to reach this target, even with uric acid-lowering therapy (ULT). This study investigated clinical characteristics of target SUA achievers among Korean patients with gout. This study used data from the ULTRA registry, a nationwide inception cohort established in September 2021 that enrolls patients with gout who initiate ULT. Demographic, clinical, and laboratory data were collected at baseline; the 6-month follow-up. Patients were divided into two groups: target achievers (SUA level < 6 mg/dL at 6 months) and non-achievers. The mean participant (N = 117) age was 56.1 years, and 88.0% were male. At 6 months, 83 patients (70.9%) reached target SUA levels. Target achievers had better drug adherence (≥ 80%) to ULT (97.6% vs. 76.5%; p < 0.01) than non-achievers. Target non-achievers had a higher percentage of a family history of gout (32.4% vs. 10.8%; p < 0.01) and less antihypertensive agent use (38.2% vs. 59.0%; p = 0.03) than target achievers. Multivariate regression analysis revealed that good adherence to ULT, the absence of a family history of gout, and antihypertensive agent use were key factors associated with achieving target SUA levels at 6 months.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry. · full record | OpenQuestion